US20030113367A1 - Alprazolam inclusion complexes and pharmaceutical compositions thereof - Google Patents

Alprazolam inclusion complexes and pharmaceutical compositions thereof Download PDF

Info

Publication number
US20030113367A1
US20030113367A1 US10/220,563 US22056302A US2003113367A1 US 20030113367 A1 US20030113367 A1 US 20030113367A1 US 22056302 A US22056302 A US 22056302A US 2003113367 A1 US2003113367 A1 US 2003113367A1
Authority
US
United States
Prior art keywords
cyclodextrin
beta
mol
inclusion complex
alprazolam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/220,563
Inventor
Lawrence Penkler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farmarc Nederland BV
Original Assignee
Farmarc Nederland BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmarc Nederland BV filed Critical Farmarc Nederland BV
Assigned to FARMARC NEDERLAND BV reassignment FARMARC NEDERLAND BV ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PENKLER, LAWRENCE JOHN
Publication of US20030113367A1 publication Critical patent/US20030113367A1/en
Priority to US11/144,965 priority Critical patent/US7202233B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Definitions

  • This invention relates to an inclusion complex of alprazolam and an unsubstituted or substituted beta- or gamma-cyclbdextrin, and to pharmaceutical compositions containing such a complex, particularly for oral, nasal or rectal mucosal delivery, for the treatment of anxiety and panic attack.
  • Alprazolam is also known as 8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine.
  • Alprazolam is indicated for the short term treatment of Generalised Anxiety Disorder (GAD) and has particular utility as an agent for the management of panic disorders (with or without agoraphobia)
  • alprazolam is well absorbed from a tablet formulation after conventional orogastric administration, maximum plasma levels occur between 0,7 to 1,8 hours post-dose. The onset of anxiolysis correlates with attainment of maximum plasma levels. The absorption rate is therefore often not sufficiently rapid to provide immediate symptomatic relief in an anxiety crisis. Absorption of alprazolam from the stomach is further adversely affected by the presence of food and antacids, the use of the latter being frequently associated with stress related syndromes. Rapid absorption of alprazolam in a manner which would avoid these complications and avoid the need for administration of the dosage form with a liquid would have distinct advantages.
  • the mucosal route of drug delivery offers a useful alternative to parenteral delivery where a rapid therapeutic effect is desired.
  • Sublingual use of the commercially available oral tablet dosage forms of alprazolam offers no significant benefit over conventional orogastric administration in terms of speed of onset [see J. M. Scavone et al, J. Clin. Psychopharmacol., 1987, 7, 332-335].
  • Formulation of alprazolam in a manner which permits rapid uptake from the sublingual, nasal or rectal mucosa would have distinct utility in the emergency relief of anxiety symptoms.
  • the oral, nasal and rectal cavities have several advantages as sites for systemic drug delivery, particularly avoidance of pre-systemic metabolism.
  • the low permeability of the membranes that line the oral and nasal cavities result in a low flux of drug.
  • the absorption of drugs from mucosal membranes may be enhanced by (i) increasing drug solubility, (ii) pH modification to favour the unionised form of the drug, (iii) addition of mucoadhesive agents to improve contact between the delivery system and the membrane and (iv) incorporation of so-called penetration enhancers.
  • Cyclodextrins and their derivatives have found extensive application as solubilizers and stabilizers due to their ability to form inclusion complexes with a wide variety of compounds (see J. Szejtli, Cyclodextrin Technology, Kluwer Academic Press) and (J. Szejtli & K-H Fromming, Cyclodextrins in Pharmacy, Kluwer Academic Press). Cyclodextrins have been used to enhance intenstinal absorption of drugs primarily through increasing solubility. Recently, cyclodextrins have been shown to have positive and negative effects on transdermal penetration of drugs (see Loftsson, T. et al International Journal of Pharmaceutics 1995, 115, 255-258), (Vollmer, U.
  • Cyclodextrins may improve nasal absorption of drugs (see Merkus, F. W. et al. Pharmaceutical Research 1992, 9, 1157-1163) and enhance absorption from sublingual administration of drug/cyclodextrin complexes. Cyclodextrins also protect nasal mucosal damage by penetration enhancers (see Jabbal. Gill, I. et al. European Journal of Pharmaceutical Sciences 1994, 1 (5), 229-236).
  • Cyclodextrins are water soluble cone-shaped cyclic oligosaccharides containing 6, 7 or 8 glucopyranose units.
  • the interior or “cavity” of the cone is hydrophobic whilst the exterior is hydrophilic.
  • the size of the cavity increases with increasing number of glucose units.
  • cyclodextrin derivatives such as alkyl, hydroxyalkyl and sulfoalkyl ethers have been prepared with improved solubility (see J. Szejtli & K-H Fromming, Cyclodextrins in Pharmacy, Kluwer Academic Press) and (Stella, V. J. et al. Pharmaceutical Research 1995, 12 (9) S205).
  • Suitably sized hydrophobic “guest” molecules may enter the “host” cavity to form a classical host-guest “inclusion compound” or “inclusion complex” with either the entire guest molecule included or only a portion thereof.
  • the driving mechanism for cyclodextrin inclusion complexation is the affinity of the hydrophobic guest molecule for the cavity of the cyclodextrin host molecule with displacement of cavity water molecules to a thermodynamically more stable state.
  • complex stability or stability of a given inclusion complex refers to the association/dissociation equilibrium of host and guest in solution. Complex stability depends on the number of intermolecular bonding interactions between the host and guest. Van der Waals forces and hydrophobic interactions are the main interactions stabilising inclusion complexes (Bergeron, R.
  • Cyclodextrin inclusion complexes may be prepared on the basis of liquid state, solid state or semi-solid state reaction between the components (J. Szejtli, Cyclodextrin Technology, Kluwer Academic Press). The first is accomplished by dissolving the cyclodextrin and guest in a suitable solvent or mixture of solvents and subsequently isolating the solid state complex by crystallisation, evaporation, spray drying or freeze drying.
  • the two components may be screened to uniform particle size and thoroughly mixed whereafter they are ground in a high energy mill with optional heating, screened and homogenised.
  • the semi-solid state the two components are kneaded in the presence of small amounts of a suitable solvent, and the complex so-formed, is dried, screened and homogenised.
  • the liquid state reaction generally provides optimum conditions for completeness of reaction. Depending on solvent conditions, the dissolved inclusion complex exists in equilibrium between uncomplexed host and guest and complexed host/guest.
  • Loftsson et al [see Int. J. Pharm, 1998, 162(2), 115-121] have also reported an enhancement in the solubility and have demonstrated improved complexing ability for ⁇ -cyclodextrin in solutions of drugs containing water soluble polymers, including the drug alprazolam. No solid complex is described.
  • a pharmaceutical composition for transmucosal delivery comprising an inclusion complex of (a) alprazolam and (b) a water soluble unsubstituted or substituted beta- or gamma-cyclodextrin, and a pharmaceutically acceptable carrier therefor.
  • the pharmaceutically acceptable carrier must be suitable for transmucosal delivery of the alprazolam inclusion complex.
  • the cyclodextrin is preferably a water soluble unsubstituted or substituted beta-cyclodextrin, more preferably an alkylated beta-cyclodextrin, a hydroxyalkylated beta-cyclodextrin, or a sulfoalkylated beta-cyclodextrin.
  • the inclusion complex is preferably an inclusion complex of alprazolam and 2-hydroxypropyl-beta-cycodextrin, of alprazolam and a randomly methylated-beta-cyclodextrin, or of alprazolam and sulfobutyl ether beta-cyclodextrin.
  • the inclusion complex preferably has a stoichiometry of (a) to (b) from 1:1 mol/mol to 1:10 mol/mol inclusive and more preferably 1:7 mol/mol inclusive.
  • an inclusion complex of (a) alprazolam and (b) a water soluble unsubstituted or substituted beta- or gamma- cyclodextrin.
  • the pharmaceutical composition is preferably for use in the treatment of Generalised Anxiety Disorder (GAD) and has particular utility as an agent for the management of panic disorders.
  • GAD Generalised Anxiety Disorder
  • the pharmaceutical composition is preferably adapted for oral, nasal or rectal mucosal delivery.
  • FIG. 1 represents the effect of varying concentrations of beta-cyclodextrin (BCD) on the aqueous solubility of alprazolam at 25° C.
  • BCD beta-cyclodextrin
  • FIG. 2 represents the effect of methyl-beta cyclodextrin (squares) and 2-hydroxypropyl-beta-cyclodextrin (triangles) on the aqueous solubility of alprazolam at 25° C.
  • FIG. 3 represents the dissolution rate of alprazolam from a physical mixture (solid squares) of alprazolam and 2-hydroxypropyl-beta-cyclodextrin and the corresponding complex (open diamonds) obtained from Example 3 and performed according to Example 5.
  • FIG. 4 represents the dissolution rate of alprazolam from a physical mixture (solid squares) of alprazolam and methyl-beta-cyclodextrin and the corresponding complex (open diamonds) obtained from Example 4 and performed according to Example 5.
  • the powder samples were compressed into disks using a single punch and die.
  • the crux of the invention is an inclusion complex of (a) alprazolam and (b) an unsubstituted or substituted beta- or gamma-cyclodextrin, and pharmaceutical compositions containing the inclusion complex for transmucosal delivery.
  • the second component of the inclusion complex is an unsubstituted or substituted beta- or gamma-cyclodextrin.
  • cyclodextrins such as 2-hydroxypropylated or randomly methylated or sulfoalkylated derivatives of beta-cyclodextrin are the preferred cyclodextrins of the invention.
  • Gamma-cyclodextrin or 2-hydroxypropylated or randomly methylated or sulfoalkylated derivatives of gamma-cyclodextrin may also be used in the same manner as the corresponding preferred beta-cyclodextrin derivatives.
  • the degree of substitution of the cyclodextrin derivatives may vary between 1 to 20 substituents per cyclodextrin molecule, but more preferably between 3 to 15 substituents per cyclodextrin molecule.
  • the preferred degree of substitution is between 3,9 and 5,1 hydroxypropyl groups per cyclodextrin molecule.
  • the preferred degree of substitution is between 1,8 and 2 methyl groups per glucose unit.
  • the preferred degree of substitution is between 1 and 7 sulfobutyl ether groups per cyclodextrin molecule.
  • the inclusion complex of the invention may be prepared from aqueous solutions, slurries or pastes of alprazolam and cyclodextrin according to conventional methods.
  • the molar ratio of alprazolam to cyclodextrin may vary between 1:1 to 1:10 inclusive, but more preferably between 1:1 to 1:7 inclusive.
  • Solutions are prepared by dissolving the cyclodextrin in a sufficient quantity of purified deionised water. Alprazolam is added to the solution with stirring until dissolved.
  • the solution may be used in the preparation of liquid delivery systems such as drops, sprays or aerosols. Where a solid inclusion complex is desired, the solution or slurry may be dried by spray drying or freeze drying.
  • alprazolam and cyclodextrin are mixed.
  • the powder mixture is wetted with water while mixing vigorously until a paste is formed.
  • the paste is mixed for 0,25 to 2 hours and dried in an oven or in vacuo at elevated temperature. The dried complex is crushed and sieved to the desired particle size.
  • the particle size of the complex is preferably 95% less than 100 microns and most preferably 95% less than 50 microns, to facilitate wetting of a solid formulation.
  • the second aspect of the invention is a pharmaceutical composition which comprises as an active ingredient an inclusion complex as described above.
  • composition of the invention is of particular application in the treatment of GAD and for the management of panic disorders.
  • the pharmaceutical composition of the invention is preferably adapted for oral, nasal, or rectal mucosal delivery.
  • anxiolytic drug through the mucosal tissue of the nose, mouth or rectum avoids the problems associated with oral administration of alprazolam (i.e. slow onset of action, low bio-availability and associated poor compliance).
  • the unpleasant taste and irritant properties of the active principle are reduced by presenting the drug to the nasal or rectal oral mucosal membranes in the form of a cyclodextrin inclusion complex.
  • the present invention achieves these advantages by molecular encapsulation of the drug in a cyclodextrin, so forming a molecular inclusion complex which may be used in the solid form for the preparation of sublingual or buccal tablets, buccal patches, nasal inhalation powders (insufflations), suppositories, or powder aerosols for nasal or pulmonary application.
  • the inclusion complex may be used in the liquid state for the preparation of metered dose sprays, drops or pressurised aerosols for nasal or oral administration.
  • the complex according to the invention may be incorporated into a shearform matrix designed for immediate release as described in Fuisz Technolgies Ltd. patents (Eur. Pat. Appl. EP 95-650038 and PCT Int. Appl. WO 95/34293).
  • the water soluble complexes of alprazolam according to the invention may be incorporated into controlled release matrices for sustained release following oral administration of a matrix tablet.
  • the matrix may be composed of any suitable erodible matrix such as substituted celluloses and the like.
  • the complexes may be applied to non-pareil spheres by coating methods known in the art.
  • the coated spheres may be optionally coated with controlled release polymers such as polyacrylates and the like.
  • alprazolam has been found to be included in the cavity of beta- and gamma-cyclodextrins to form molecular inclusion complexes.
  • Inclusion complexes of alprazolam may therefore be prepared according to methods known in the art such as spray drying, freeze drying and kneading, as described above.
  • the complexes according to the invention may also be incorporated into microspheres by methods appreciated in the art.
  • the complexes according to the invention are stable and highly water soluble.
  • Penetration enhancers may be used to promote the passage of alprazolam across the mucosal membranes.
  • Typical permeation enhancers include fatty acids and their salts such as sodium caprate, sodium caprylate and sodium oleate, sodium laurate, and bile salts such as sodium glycodeoxycholate, sodium glycocholate, sodium cholate and sodium laurodeoxycholate.
  • Other penetration enhancers may include tensides, ionic surfactants such as sodium lauryl sulphate, or non-ionic surfactants such as polyethylene glycol 660 hydroxystearate or polyoxyethylene lauryl ethers, fusidates such as sodium taurodihydrofusidate.
  • Typical concentrations of permeation enhancers are between 0,1% to 5%, more preferably between 0,25% to 3% by weight of the composition.
  • Liquid compositions suitable for nasal or oral administration may contain a suitable quantity of viscosity modifying agents such as hypromellose or carbopol 934P and preservative agents such as benzalkonium chloride, chlorhexidine gluconate or thiomersat.
  • viscosity modifying agents such as hypromellose or carbopol 934P
  • preservative agents such as benzalkonium chloride, chlorhexidine gluconate or thiomersat.
  • Oral compositions may contain suitable flavouring and sweetening agents such as cherry, mint, spearmint, vanilla, aspartame, sucrose, xylitol, saccharin and the like.
  • Typical sublingual or buccal tablets may include lubricants such as magnesium stearate, calcium stearate and sodium stearyl fumarate to facilitate tablet compression, diluents such as lactose, microcrystalline cellulose, maize starch and the like and mucoadhesive agents such as chitosan, carbopol 934P, and hydroxypropylcellulose and the like.
  • lubricants such as magnesium stearate, calcium stearate and sodium stearyl fumarate to facilitate tablet compression
  • diluents such as lactose, microcrystalline cellulose, maize starch and the like
  • mucoadhesive agents such as chitosan, carbopol 934P, and hydroxypropylcellulose and the like.
  • Typical disintegrants to enhance sublingual tablet disintegration may include sodium carboxymethylcellulose, sodium starch glycolate, polyplasdone XL, and dried starch.
  • Typical suppositories may be formulated according to methods known in the art described in the Pharmaceutical Codex 12 th Edition, the Pharmaceutical Press, pp 170-176 or Remington's Pharmaceutical Sciences 18 th Edition, Mack Publishing Company, pp 1609-1614.
  • alprazolam is added to aqueous solutions of varying concentrations of beta-cyclodextrin. The mixtures are shaken for 24 hours and filtered. The filtrate is analysed by Ultraviolet spectrophotometry for alprazolam concentration. The concentration of alprazolam is plotted as a function of beta-cyclodextrin concentration in FIG. 1.
  • alprazolam is added to aqueous solutions of varying concentrations of methyl-beta-cyclodextrin and 2-hydroxypropyl-beta-cyclodextrin. The mixtures are shaken for 24 hours and filtered. The filtrate is analysed by Ultraviolet spectrophotometry for alprazolam concentration. The concentration of alprazolam is plotted as a function of cyclodextrin concentration in FIG. 2.
  • Alprazolam (6,53 g) and 2-hydroxypropyl-beta-cyclodextrin (200,4 g) are mixed.
  • Purified deionised water 70 ml is added with vigorous kneading to form a uniform paste with optional heating. Kneading is continued for 5 hours and the paste is dried in vacuo at 80° C. The dried complex is crushed and passed through a 250 micron sieve.
  • Alprazolam (6,0 g) and methyl-beta-cyclodextrin (198 g) are mixed.
  • Purified deionised water 70 ml is added with vigorous kneading to form a uniform paste with optional heating. Kneading is continued for 5 hours and the paste is dried in vacuo at 80° C. The dried complex is crushed and passed through a 250 micron sieve.
  • the unit composition of a sublingual tablet containing the equivalent of 1,0 mg alprazolam is as follows: Alprazolam/2-hydroxypropyl-beta-cyclodextrin complex 32.7 mg (from Example 3) Lactose NF 19 mg Sodium stearyl fumarate 0.6 mg
  • the complex is blended with lactose and the lubricant.
  • the mixture is formed into sublingual tablets by compression at 10-30 N.
  • Methylated beta-cyclodextrin D.S.1.8 (200 g) is dissolved in 90 ml purified deionised water.
  • Alprazolam (2.5 g) is added to the solution with stirring until a clear solution is obtained.
  • Benzalkonium chloride (0.01%) is added as a preservative.
  • the volume is adjusted to 1000 ml by addition of purified deionised water.
  • the tonicity of the final solution is adjusted by addition of sodium chloride.
  • the solution is filtered through a 0.45 ⁇ m filter. Each 0.1 milliliter of solution contains 0.25 mg alprazolam. The solution is well tolerated after intranasal administration by drops or spray.
  • Example 8 The solution obtained from Example 8 is packaged in a suitable metered dose aerosol dispenser adapted for intranasal application.
  • the concentration of the solution provides convenient dispensing of 0.25 mg alprazolam per 0.1 ml.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pharmaceutical composition for transmucosal delivery contains an inclusion complex of alprazolam and a water soluble unsubstituted or substituted beta- or gamama-cyclodextiin such as 2-hydroxypropyl beta-cyclodextfin, and a pharmaceutically acceptable carrier therefor. The pharmaceutical composition is of particular application in the treatment of Generalised Anxiety Disorder or for the management of panic disorders.

Description

    BACKGROUND OF THE INVENTION
  • This invention relates to an inclusion complex of alprazolam and an unsubstituted or substituted beta- or gamma-cyclbdextrin, and to pharmaceutical compositions containing such a complex, particularly for oral, nasal or rectal mucosal delivery, for the treatment of anxiety and panic attack. [0001]
  • Alprazolam is also known as 8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine. [0002]
  • Alprazolam is indicated for the short term treatment of Generalised Anxiety Disorder (GAD) and has particular utility as an agent for the management of panic disorders (with or without agoraphobia) [0003]
  • In an acute state such as a panic attack, a rapid onset of action is desirable. Although alprazolam is well absorbed from a tablet formulation after conventional orogastric administration, maximum plasma levels occur between 0,7 to 1,8 hours post-dose. The onset of anxiolysis correlates with attainment of maximum plasma levels. The absorption rate is therefore often not sufficiently rapid to provide immediate symptomatic relief in an anxiety crisis. Absorption of alprazolam from the stomach is further adversely affected by the presence of food and antacids, the use of the latter being frequently associated with stress related syndromes. Rapid absorption of alprazolam in a manner which would avoid these complications and avoid the need for administration of the dosage form with a liquid would have distinct advantages. [0004]
  • The mucosal route of drug delivery, in particular the sublingual or nasal mucosal routes, offer a useful alternative to parenteral delivery where a rapid therapeutic effect is desired. Sublingual use of the commercially available oral tablet dosage forms of alprazolam offers no significant benefit over conventional orogastric administration in terms of speed of onset [see J. M. Scavone et al, J. Clin. Psychopharmacol., 1987, 7, 332-335]. Formulation of alprazolam in a manner which permits rapid uptake from the sublingual, nasal or rectal mucosa would have distinct utility in the emergency relief of anxiety symptoms. [0005]
  • The oral, nasal and rectal cavities have several advantages as sites for systemic drug delivery, particularly avoidance of pre-systemic metabolism. However, the low permeability of the membranes that line the oral and nasal cavities result in a low flux of drug. There is therefore a need to enhance drug solubility and penetration to improve bioavailability following oral or nasal mucosal drug delivery. [0006]
  • There are several methods known in the art to deliver drugs to the oral, nasal and rectal mucosae. These include buccal and sublingual tablets or lozenges, adhesive patches, gels, solutions or sprays (powder, liquid or aerosol) for the oral cavity and solutions or sprays (powder, liquid or aerosol) for the nasal cavity and suppositories for rectal administration. [0007]
  • The absorption of drugs from mucosal membranes may be enhanced by (i) increasing drug solubility, (ii) pH modification to favour the unionised form of the drug, (iii) addition of mucoadhesive agents to improve contact between the delivery system and the membrane and (iv) incorporation of so-called penetration enhancers. [0008]
  • There are a number of penetration enhancers known to influence the permeability of drugs across epithelial membranes (for a recent review see Walker, R. B. and Smith, E. W. Advanced Drug Delivery Reviews 1996, 18, 295-301). [0009]
  • Cyclodextrins and their derivatives have found extensive application as solubilizers and stabilizers due to their ability to form inclusion complexes with a wide variety of compounds (see J. Szejtli, Cyclodextrin Technology, Kluwer Academic Press) and (J. Szejtli & K-H Fromming, Cyclodextrins in Pharmacy, Kluwer Academic Press). Cyclodextrins have been used to enhance intenstinal absorption of drugs primarily through increasing solubility. Recently, cyclodextrins have been shown to have positive and negative effects on transdermal penetration of drugs (see Loftsson, T. et al International Journal of Pharmaceutics 1995, 115, 255-258), (Vollmer, U. et al. International Journal of Pharmaceutics 1993, 99, 51-58), (Legendre, J. Y. et al. European Journal of Pharmaceutics 1995, 3, 311-322) and (Vollmer, U. et al Journal of Pharmacy and Pharmacology 1994, 46, 19-22). Cyclodextrins may improve nasal absorption of drugs (see Merkus, F. W. et al. Pharmaceutical Research 1992, 9, 1157-1163) and enhance absorption from sublingual administration of drug/cyclodextrin complexes. Cyclodextrins also protect nasal mucosal damage by penetration enhancers (see Jabbal. Gill, I. et al. European Journal of Pharmaceutical Sciences 1994, 1 (5), 229-236). Cyclodextrins are water soluble cone-shaped cyclic oligosaccharides containing 6, 7 or 8 glucopyranose units. The interior or “cavity” of the cone is hydrophobic whilst the exterior is hydrophilic. The size of the cavity increases with increasing number of glucose units. Several cyclodextrin derivatives such as alkyl, hydroxyalkyl and sulfoalkyl ethers have been prepared with improved solubility (see J. Szejtli & K-H Fromming, Cyclodextrins in Pharmacy, Kluwer Academic Press) and (Stella, V. J. et al. Pharmaceutical Research 1995, 12 (9) S205). Suitably sized hydrophobic “guest” molecules may enter the “host” cavity to form a classical host-guest “inclusion compound” or “inclusion complex” with either the entire guest molecule included or only a portion thereof. The driving mechanism for cyclodextrin inclusion complexation is the affinity of the hydrophobic guest molecule for the cavity of the cyclodextrin host molecule with displacement of cavity water molecules to a thermodynamically more stable state. The term “complex stability” or stability of a given inclusion complex refers to the association/dissociation equilibrium of host and guest in solution. Complex stability depends on the number of intermolecular bonding interactions between the host and guest. Van der Waals forces and hydrophobic interactions are the main interactions stabilising inclusion complexes (Bergeron, R. J. et al. Journal of the American Chemical Society 1977, 99, 5146). Depending on the nature and position of hydrogen bonding functionalities on a given guest, there may be hydrogen bonding between the guest and hydroxyl groups of the cyclodextrin or other hydrogen bonding groups in the case of cyclodextrin derivatives. Ionic interactions between the host and guest are also possible in the case of ionic cyclodextrins such as sulfobutyl ethers (Stella, V. J. et al. Pharmaceutical Research 1995, 12 (9), S205). [0010]
  • Cyclodextrin inclusion complexes may be prepared on the basis of liquid state, solid state or semi-solid state reaction between the components (J. Szejtli, Cyclodextrin Technology, Kluwer Academic Press). The first is accomplished by dissolving the cyclodextrin and guest in a suitable solvent or mixture of solvents and subsequently isolating the solid state complex by crystallisation, evaporation, spray drying or freeze drying. In the solid state method, the two components may be screened to uniform particle size and thoroughly mixed whereafter they are ground in a high energy mill with optional heating, screened and homogenised. In the semi-solid state, the two components are kneaded in the presence of small amounts of a suitable solvent, and the complex so-formed, is dried, screened and homogenised. [0011]
  • The liquid state reaction generally provides optimum conditions for completeness of reaction. Depending on solvent conditions, the dissolved inclusion complex exists in equilibrium between uncomplexed host and guest and complexed host/guest. [0012]
  • The use of cyclodextrins to increase the solubility of alprazolam has been described. In an article in Acta Pharm. Nord. 3(4), 1991, 215-217, Loftsson et al describe the effect of the cyclodextrin derivative, 2-hydroxypropyl-β-cyclodextrin, on the aqueous solubility of 13 different drugs, including alprazolam. A 16-fold solubility enhancement for alprazolam in a 20% solution of 2-hydroxypropyl-β-cyclodextrin is reported. No solid complex is described. [0013]
  • In a subsequent article published in Int. J. Pharm, 1994, 110, 169-177, Loftsson et al describe the effect of 2-hydroxypropyl-β-cyclodextrin on the water solubility of alprazolam in the presence and absence of water soluble polymers. Enhanced solubility of alprazolam is obtained following heating of a solution of 2-hydroxypropyl-β-cyclodextrin and a water soluble polymer in a sealed container at 120° C. for 20 minutes. No solid complex is described. [0014]
  • JP 07165616 to Hisamitsu Pharmaceutical Company, Japan similarly claims the formation of inclusion complexes of drugs with cyclodextrin in the presence of water soluble polymers to improve solubility and stability. Loftsson et al [see Int. J. Pharm, 1998, 162(2), 115-121] have also reported an enhancement in the solubility and have demonstrated improved complexing ability for β-cyclodextrin in solutions of drugs containing water soluble polymers, including the drug alprazolam. No solid complex is described. [0015]
  • DE 44 28 986 A1 to KRKA, Slovenia teaches the formulation of rapidly dissolving solid dosage forms for orogastric administration of alprazolam containing alpha-, beta-, or gamma cyclodextrin when employed as water soluble carriers. Alprazolam is deposited on the carrier by spray drying prior to incorporation into a tablet. [0016]
  • U.S. Pat. Nos. 5,288,497 and 5,785,989 to Stanley, T. H. et al (The University of Utah) entitled “Compositions of Oral Dissolvable Medicaments” and “Compositions and Methods of Manufacturing of Oral Dissolvable Medicaments”, respectively, recite in their claims a drug-containing dosage form (where the drug is a benzodiazepine) which permits absorption through the mucosal tissues of the mouth. The dosage form is referred to as an “appliance or holder” containing drug dispersed into a carbohydrate, fat, protein, wax or other dissolvable matrix. [0017]
    • SUMMARY OF THE INVENTION
  • According to a first aspect of the invention there is provided a pharmaceutical composition for transmucosal delivery comprising an inclusion complex of (a) alprazolam and (b) a water soluble unsubstituted or substituted beta- or gamma-cyclodextrin, and a pharmaceutically acceptable carrier therefor. [0018]
  • The pharmaceutically acceptable carrier must be suitable for transmucosal delivery of the alprazolam inclusion complex. [0019]
  • The cyclodextrin is preferably a water soluble unsubstituted or substituted beta-cyclodextrin, more preferably an alkylated beta-cyclodextrin, a hydroxyalkylated beta-cyclodextrin, or a sulfoalkylated beta-cyclodextrin. [0020]
  • The inclusion complex is preferably an inclusion complex of alprazolam and 2-hydroxypropyl-beta-cycodextrin, of alprazolam and a randomly methylated-beta-cyclodextrin, or of alprazolam and sulfobutyl ether beta-cyclodextrin. [0021]
  • The inclusion complex preferably has a stoichiometry of (a) to (b) from 1:1 mol/mol to 1:10 mol/mol inclusive and more preferably 1:7 mol/mol inclusive. [0022]
  • According to a second aspect of the invention there is provided an inclusion complex of (a) alprazolam and (b) a water soluble unsubstituted or substituted beta- or gamma- cyclodextrin. [0023]
  • The pharmaceutical composition is preferably for use in the treatment of Generalised Anxiety Disorder (GAD) and has particular utility as an agent for the management of panic disorders. [0024]
  • The pharmaceutical composition is preferably adapted for oral, nasal or rectal mucosal delivery.[0025]
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 represents the effect of varying concentrations of beta-cyclodextrin (BCD) on the aqueous solubility of alprazolam at 25° C. [0026]
  • FIG. 2 represents the effect of methyl-beta cyclodextrin (squares) and 2-hydroxypropyl-beta-cyclodextrin (triangles) on the aqueous solubility of alprazolam at 25° C. [0027]
  • FIG. 3 represents the dissolution rate of alprazolam from a physical mixture (solid squares) of alprazolam and 2-hydroxypropyl-beta-cyclodextrin and the corresponding complex (open diamonds) obtained from Example 3 and performed according to Example 5. [0028]
  • FIG. 4 represents the dissolution rate of alprazolam from a physical mixture (solid squares) of alprazolam and methyl-beta-cyclodextrin and the corresponding complex (open diamonds) obtained from Example 4 and performed according to Example 5. The powder samples were compressed into disks using a single punch and die.[0029]
    • DESCRIPTION OF EMBODIMENTS
  • The crux of the invention is an inclusion complex of (a) alprazolam and (b) an unsubstituted or substituted beta- or gamma-cyclodextrin, and pharmaceutical compositions containing the inclusion complex for transmucosal delivery. [0030]
  • The second component of the inclusion complex is an unsubstituted or substituted beta- or gamma-cyclodextrin. [0031]
  • Highly water soluble cyclodextrins such as 2-hydroxypropylated or randomly methylated or sulfoalkylated derivatives of beta-cyclodextrin are the preferred cyclodextrins of the invention. Gamma-cyclodextrin or 2-hydroxypropylated or randomly methylated or sulfoalkylated derivatives of gamma-cyclodextrin may also be used in the same manner as the corresponding preferred beta-cyclodextrin derivatives. The degree of substitution of the cyclodextrin derivatives may vary between 1 to 20 substituents per cyclodextrin molecule, but more preferably between 3 to 15 substituents per cyclodextrin molecule. [0032]
  • When the cyclodextrin is 2-hydroxypropyl-beta-cyclodextrin, the preferred degree of substitution is between 3,9 and 5,1 hydroxypropyl groups per cyclodextrin molecule. When the cyclodextrin is a randomly methylated-beta-cyclodextrin, the preferred degree of substitution is between 1,8 and 2 methyl groups per glucose unit. When the cyclodextrin is sulfobutyl ether-beta-cyclodextrin, the preferred degree of substitution is between 1 and 7 sulfobutyl ether groups per cyclodextrin molecule. [0033]
  • The inclusion complex of the invention may be prepared from aqueous solutions, slurries or pastes of alprazolam and cyclodextrin according to conventional methods. The molar ratio of alprazolam to cyclodextrin may vary between 1:1 to 1:10 inclusive, but more preferably between 1:1 to 1:7 inclusive. Solutions are prepared by dissolving the cyclodextrin in a sufficient quantity of purified deionised water. Alprazolam is added to the solution with stirring until dissolved. The solution may be used in the preparation of liquid delivery systems such as drops, sprays or aerosols. Where a solid inclusion complex is desired, the solution or slurry may be dried by spray drying or freeze drying. [0034]
  • Alternatively, alprazolam and cyclodextrin are mixed. The powder mixture is wetted with water while mixing vigorously until a paste is formed. The paste is mixed for 0,25 to 2 hours and dried in an oven or in vacuo at elevated temperature. The dried complex is crushed and sieved to the desired particle size. [0035]
  • The particle size of the complex is preferably 95% less than 100 microns and most preferably 95% less than 50 microns, to facilitate wetting of a solid formulation. [0036]
  • The second aspect of the invention is a pharmaceutical composition which comprises as an active ingredient an inclusion complex as described above. [0037]
  • The pharmaceutical composition of the invention is of particular application in the treatment of GAD and for the management of panic disorders. [0038]
  • Further, the pharmaceutical composition of the invention is preferably adapted for oral, nasal, or rectal mucosal delivery. [0039]
  • The administration of an anxiolytic drug through the mucosal tissue of the nose, mouth or rectum avoids the problems associated with oral administration of alprazolam (i.e. slow onset of action, low bio-availability and associated poor compliance). [0040]
  • Absorption of the drug from the pharmaceutical composition of the invention is rapid such that the drug reaches the systemic circulation almost as fast as through injection and appreciably faster than oral administration, which is highly advantageous for the rapid relief of anxiety. [0041]
  • Further, the unpleasant taste and irritant properties of the active principle are reduced by presenting the drug to the nasal or rectal oral mucosal membranes in the form of a cyclodextrin inclusion complex. [0042]
  • The present invention achieves these advantages by molecular encapsulation of the drug in a cyclodextrin, so forming a molecular inclusion complex which may be used in the solid form for the preparation of sublingual or buccal tablets, buccal patches, nasal inhalation powders (insufflations), suppositories, or powder aerosols for nasal or pulmonary application. The inclusion complex may be used in the liquid state for the preparation of metered dose sprays, drops or pressurised aerosols for nasal or oral administration. The complex according to the invention may be incorporated into a shearform matrix designed for immediate release as described in Fuisz Technolgies Ltd. patents (Eur. Pat. Appl. EP 95-650038 and PCT Int. Appl. WO 95/34293). [0043]
  • The water soluble complexes of alprazolam according to the invention may be incorporated into controlled release matrices for sustained release following oral administration of a matrix tablet. The matrix may be composed of any suitable erodible matrix such as substituted celluloses and the like. Alternatively the complexes may be applied to non-pareil spheres by coating methods known in the art. The coated spheres may be optionally coated with controlled release polymers such as polyacrylates and the like. [0044]
  • According to the invention, alprazolam has been found to be included in the cavity of beta- and gamma-cyclodextrins to form molecular inclusion complexes. Inclusion complexes of alprazolam may therefore be prepared according to methods known in the art such as spray drying, freeze drying and kneading, as described above. The complexes according to the invention may also be incorporated into microspheres by methods appreciated in the art. The complexes according to the invention are stable and highly water soluble. [0045]
  • Penetration enhancers may be used to promote the passage of alprazolam across the mucosal membranes. Typical permeation enhancers include fatty acids and their salts such as sodium caprate, sodium caprylate and sodium oleate, sodium laurate, and bile salts such as sodium glycodeoxycholate, sodium glycocholate, sodium cholate and sodium laurodeoxycholate. Other penetration enhancers may include tensides, ionic surfactants such as sodium lauryl sulphate, or non-ionic surfactants such as polyethylene glycol 660 hydroxystearate or polyoxyethylene lauryl ethers, fusidates such as sodium taurodihydrofusidate. Other specific enhancers include azone and chitosan. Combinations of permeation enhancers such as [0046] polyoxyethylene 8 lauryl ether and sodium glycocholate or mixed micelles such as sodium caprate and sodium glycocholate may also be used. The penetration enhancers may also be used in combination with sulfoalkyl derivatives. Typical concentrations of permeation enhancers are between 0,1% to 5%, more preferably between 0,25% to 3% by weight of the composition.
  • Liquid compositions suitable for nasal or oral administration may contain a suitable quantity of viscosity modifying agents such as hypromellose or carbopol 934P and preservative agents such as benzalkonium chloride, chlorhexidine gluconate or thiomersat. [0047]
  • Oral compositions may contain suitable flavouring and sweetening agents such as cherry, mint, spearmint, vanilla, aspartame, sucrose, xylitol, saccharin and the like. [0048]
  • Typical sublingual or buccal tablets may include lubricants such as magnesium stearate, calcium stearate and sodium stearyl fumarate to facilitate tablet compression, diluents such as lactose, microcrystalline cellulose, maize starch and the like and mucoadhesive agents such as chitosan, carbopol 934P, and hydroxypropylcellulose and the like. [0049]
  • Typical disintegrants to enhance sublingual tablet disintegration may include sodium carboxymethylcellulose, sodium starch glycolate, polyplasdone XL, and dried starch. [0050]
  • Typical suppositories may be formulated according to methods known in the art described in the [0051] Pharmaceutical Codex 12th Edition, the Pharmaceutical Press, pp 170-176 or Remington's Pharmaceutical Sciences 18th Edition, Mack Publishing Company, pp 1609-1614.
  • The following examples illustrate the present invention. [0052]
    • EXAMPLE 1
  • An excess of alprazolam is added to aqueous solutions of varying concentrations of beta-cyclodextrin. The mixtures are shaken for 24 hours and filtered. The filtrate is analysed by Ultraviolet spectrophotometry for alprazolam concentration. The concentration of alprazolam is plotted as a function of beta-cyclodextrin concentration in FIG. 1. [0053]
    • EXAMPLE 2
  • An excess of alprazolam is added to aqueous solutions of varying concentrations of methyl-beta-cyclodextrin and 2-hydroxypropyl-beta-cyclodextrin. The mixtures are shaken for 24 hours and filtered. The filtrate is analysed by Ultraviolet spectrophotometry for alprazolam concentration. The concentration of alprazolam is plotted as a function of cyclodextrin concentration in FIG. 2. [0054]
    • EXAMPLE 3
  • Alprazolam (6,53 g) and 2-hydroxypropyl-beta-cyclodextrin (200,4 g) are mixed. Purified deionised water (70 ml) is added with vigorous kneading to form a uniform paste with optional heating. Kneading is continued for 5 hours and the paste is dried in vacuo at 80° C. The dried complex is crushed and passed through a 250 micron sieve. [0055]
    • EXAMPLE 4
  • Alprazolam (6,0 g) and methyl-beta-cyclodextrin (198 g) are mixed. Purified deionised water (70 ml) is added with vigorous kneading to form a uniform paste with optional heating. Kneading is continued for 5 hours and the paste is dried in vacuo at 80° C. The dried complex is crushed and passed through a 250 micron sieve. [0056]
    • EXAMPLE 5
  • Dissolution behaviour of the inclusion complexes prepared in Examples 3 and 4 and their corresponding physical mixtures were evaluated in [0057] phosphate buffer pH 6,8 using USP Apparatus I (basket, 100 rpm, 500 ml, 37° C.). Compressed disks (200 mg) containing an amount of inclusion complex or physical mixture equivalent to 1 mg alprazolam were prepared using a single punch and die. The dissolution rate of alprazolam from the systems is shown in FIGS. 3 and 4.
  • The complexes of Examples 3 and 5 result in a significantly faster dissolution rate within the first 20 minutes compared with the physical mixture. [0058]
    • EXAMPLE 6
  • The unit composition of a sublingual tablet containing the equivalent of 1,0 mg alprazolam is as follows: [0059]
    Alprazolam/2-hydroxypropyl-beta-cyclodextrin complex 32.7 mg
    (from Example 3)
    Lactose NF 19 mg
    Sodium stearyl fumarate 0.6 mg
  • The complex is blended with lactose and the lubricant. The mixture is formed into sublingual tablets by compression at 10-30 N. [0060]
    • EXAMPLE 7
  • The powdered inclusion complexes prepared according to Examples 3 and 4 were stored in an oven at 60° C. Chromatographic analysis showed the complexes to be chemically stable after one months storage at 60° C. [0061]
    • EXAMPLE 8
  • Methylated beta-cyclodextrin D.S.1.8 (200 g) is dissolved in 90 ml purified deionised water. Alprazolam (2.5 g) is added to the solution with stirring until a clear solution is obtained. Benzalkonium chloride (0.01%) is added as a preservative. The volume is adjusted to 1000 ml by addition of purified deionised water. The tonicity of the final solution is adjusted by addition of sodium chloride. The solution is filtered through a 0.45 μm filter. Each 0.1 milliliter of solution contains 0.25 mg alprazolam. The solution is well tolerated after intranasal administration by drops or spray. [0062]
    • EXAMPLE 9
  • The solution obtained from Example 8 is packaged in a suitable metered dose aerosol dispenser adapted for intranasal application. The concentration of the solution provides convenient dispensing of 0.25 mg alprazolam per 0.1 ml. [0063]

Claims (18)

1. A pharmaceutical composition for transmucosal delivery comprising an inclusion complex of (a) alprazolam and (b) a water soluble unsubstituted or substituted beta-or gamma-cyclodextrin, and a pharmaceutically acceptable carrier therefor.
2. A pharmaceutical composition according to claim 1 wherein the cyclodextrin is a water soluble unsubstituted or substituted beta-cyclodextrin.
3. A pharmaceutical composition according to claim 2 wherein the water soluble beta-cyclodextrin is selected from the group consisting of an alkylated beta-cyclodextrin, a hydroxyalkylated beta-cyclodextrin, and a sulfoakylated beta-cyclodextrin.
4. A pharmaceutical composition according to claim 1 wherein the cyclodextrin is selected from the group consisting of 2-hydroxypropyl-beta-cyclodextrin with a degree of substitution between 3,9 and 5,1 hydroxypropyl groups per cyclodextrin molecule, a randomly methylated beta-cyclodextrin with a degree of substitution between 1,8 and 2 methyl groups per glucose unit, and sulfobutyl ether-beta-cyclodextrin with a degree of substitution between 1 and 7 sulfobutyl ether groups per cyclodextrin molecule.
5. A pharmaceutical composition according to any one of claims 1 to 4 wherein the inclusion complex has a stoichiometry of (a) to (b) of from 1:1 mol/mol to 1:10 mol/mol inclusive.
6. A pharmaceutical composition according to claim 5 wherein the inclusion complex has a stoichiometry of (a) to (b) of from 1:1 mol/mol to 1:7 mol/mol inclusive.
7. A pharmaceutical composition according to any one of claims 1 to 6 wherein the pharmaceutical composition comprises a solution of the inclusion complex of alprazolam and the cyclodextrin in a pharmaceutically acceptable liquid carrier.
8. A pharmaceutical composition according to claim 7 formulated for administration as drops, a spray or an aerosol.
9. A pharmaceutical composition according to any one of claims 1 to 6 wherein the inclusion complex of alprazolam and the beta-cyclodextrin is a solid mixed with or incorporated into a pharmaceutically acceptable solid carrier.
10. A pharmaceutical composition according to claim 9 formulated as sublingual tablets, buccal tablets, buccal patches, nasal inhalation powders, suppositories, and powder aerosols.
11. An inclusion complex of alprazolam and a water soluble unsutstituted or substituted beta- or gamma-cyclodextrin.
12. An inclusion complex according to claim 11 wherein the cyclodextrin is a water soluble unsubstituted or substituted beta-cyclodextrin.
13. An inclusion complex according to claim 12 wherein the water soluble beta-cyclodextrin is selected from the group consisting of an alkylated beta-cyclodextrin, a hydroxyalkylated beta-cyclodextrin, and a sulfoakylated beta-cyclodextrin.
14. An inclusion complex according to claim 11 wherein the cyclodextrin is selected from the group consisting of 2-hydroxypropyl-beta-cyclodextrin with a degree of substitution between 3,9 and 5,1 hydroxypropyl groups per cyclodextrin molecule, a randomly methylated beta-cyclodextrin with a degree of substitution between 1,8 and 2 methyl groups per glucose unit, and sulfobutyl ether-beta-cyclodextrin with a degree of substitution between 1 and 7 sulfobutyl ether groups per cyclodextrin molecule.
15. An inclusion complex according to any one of claims 11 to 14 wherein the inclusion complex has a stoichiometry of (a) to (b) of from 1:1 mol/mol to 1:10 mol/mol inclusive.
16. An inclusion complex according to claim 15 wherein the inclusion complex has a stoichiometry of (a) to (b) of from 1:1 mol/mol to 1:7 mol/mol inclusive.
17. The use of an inclusion complex of alprazolam and a water soluble unsubstituted or substituted beta- or gamma-cyclodextrin in the manufacture of a medicament for use in the treatment of generalised anxiety disorder or for the management of panic disorders.
18. A method of treating a patient suffering from generalised anxiety disorder or of management of a patient suffering from a panic disorder comprising transmucosal administration of an inclusion complex of alprazolam and a water soluble unsubstituted or substituted beta- or gamma-cyclodextrin.
US10/220,563 2000-03-28 2001-03-08 Alprazolam inclusion complexes and pharmaceutical compositions thereof Abandoned US20030113367A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/144,965 US7202233B2 (en) 2000-03-28 2005-06-03 Alprazolam inclusion complexes and pharmaceutical compositions thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA200001567 2000-03-28
ZA2000/1567 2000-03-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/144,965 Continuation-In-Part US7202233B2 (en) 2000-03-28 2005-06-03 Alprazolam inclusion complexes and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
US20030113367A1 true US20030113367A1 (en) 2003-06-19

Family

ID=25588686

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/220,563 Abandoned US20030113367A1 (en) 2000-03-28 2001-03-08 Alprazolam inclusion complexes and pharmaceutical compositions thereof
US11/144,965 Expired - Fee Related US7202233B2 (en) 2000-03-28 2005-06-03 Alprazolam inclusion complexes and pharmaceutical compositions thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/144,965 Expired - Fee Related US7202233B2 (en) 2000-03-28 2005-06-03 Alprazolam inclusion complexes and pharmaceutical compositions thereof

Country Status (7)

Country Link
US (2) US20030113367A1 (en)
EP (1) EP1267941B1 (en)
AU (1) AU4866001A (en)
CA (1) CA2401424C (en)
DE (1) DE60115217T2 (en)
ES (1) ES2253364T3 (en)
WO (1) WO2001072338A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060147516A1 (en) * 2005-01-06 2006-07-06 Cima Labs Inc. Taste masking system for alprazolam
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070232566A1 (en) * 2006-03-28 2007-10-04 Curtis Wright Formulations Of Low Dose Diclofenac And Beta-Cyclodextrin
US20090312724A1 (en) * 2007-06-28 2009-12-17 Cydex Pharmaceuticals, Inc. Nasal and Ophthalmic Delivery of Aqueous Corticosteroid Solutions
US9827324B2 (en) 2003-12-31 2017-11-28 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US10709662B1 (en) 2020-01-29 2020-07-14 King Abdulaziz University Mucoadhesive buccal film having a dual release carrier system
CN113908295A (en) * 2021-11-12 2022-01-11 郑州大学第一附属医院 Alprazolam clathrate and preparation method thereof
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
EP2042161A1 (en) * 1997-10-01 2009-04-01 Novadel Pharma Inc. Propellant-free spray composition comprising anti-emetic agent
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20090162300A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
AU2003247876B2 (en) 2002-07-05 2006-10-05 Collegium Pharmaceutical, Inc Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8840928B2 (en) 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
LT1765292T (en) 2004-06-12 2018-01-10 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
WO2007123955A2 (en) * 2006-04-19 2007-11-01 Novadel Pharma Inc. Stable hydroalcoholic oral spray formulations and methods
JP2010513525A (en) * 2006-12-22 2010-04-30 ノヴァデル ファーマ インコーポレイテッド Stable anti-emetic oral spray formulations and methods
CA2687085A1 (en) * 2007-05-10 2008-11-20 Novadel Pharma Inc. Anti-insomnia compositions and methods
US7985325B2 (en) * 2007-10-30 2011-07-26 Novellus Systems, Inc. Closed contact electroplating cup assembly
EP2106786A1 (en) * 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmaceutical preparation comprising permethylated cyclodextrin
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CN103491981B (en) 2010-12-31 2017-11-10 东塘实验室有限公司 Cell Hydration Composition Containing Cyclodextrin
US20120171184A1 (en) 2010-12-31 2012-07-05 Lajos Szente Cellular hydration compositions
EP2694076A4 (en) * 2011-04-01 2014-08-27 Cpex Pharmaceuticals Inc Nasal formulations of benzodiazepine
CN104892797B (en) * 2015-05-28 2017-03-22 天津大学 Synthesis method of sulfobutyl ether-beta-cyclodextrin with specific average substitution degree
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
WO2018026810A1 (en) * 2016-08-03 2018-02-08 Vanderbilt University Treatment methods using celastrol
KR20190104531A (en) * 2016-12-09 2019-09-10 알렉스자 파마스티칼즈, 인크. Epilepsy Treatment Methods
US20220257610A1 (en) * 2019-07-28 2022-08-18 Debasish Banerjee Enhancing drug activity through accentuated buccal/sublingual administration.
JP2023520903A (en) 2020-04-06 2023-05-22 イーストポンド・ラボラトリーズ・リミテッド COMPOSITION FOR PROMOTING CELL HYDRATION

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
DE69425948T2 (en) * 1993-12-06 2001-02-22 Takeda Chemical Industries, Ltd. Composition with improved water solubility, containing a water-insoluble or water-insoluble compound
AU759280C (en) * 1998-02-23 2004-01-22 Cyclops, Ehf High-energy cyclodextrin complexes
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
AU2002243760A1 (en) 2001-01-30 2002-08-12 Board Of Regents University Of Texas System Process for production of nanoparticles and microparticles by spray freezing into liquid

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827324B2 (en) 2003-12-31 2017-11-28 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US10799599B2 (en) 2003-12-31 2020-10-13 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US10207008B2 (en) 2003-12-31 2019-02-19 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US10159752B2 (en) 2003-12-31 2018-12-25 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20060147517A1 (en) * 2005-01-06 2006-07-06 Cima Labs Inc. Taste masking system for non-plasticizing drugs
US20060147516A1 (en) * 2005-01-06 2006-07-06 Cima Labs Inc. Taste masking system for alprazolam
US20070232566A1 (en) * 2006-03-28 2007-10-04 Curtis Wright Formulations Of Low Dose Diclofenac And Beta-Cyclodextrin
US8946292B2 (en) 2006-03-28 2015-02-03 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
US8580954B2 (en) 2006-03-28 2013-11-12 Hospira, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
US20110218247A1 (en) * 2006-03-28 2011-09-08 Curtis Wright Formulations of low dose diclofenac and beta-cyclodextrin
US20090312724A1 (en) * 2007-06-28 2009-12-17 Cydex Pharmaceuticals, Inc. Nasal and Ophthalmic Delivery of Aqueous Corticosteroid Solutions
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
US10709662B1 (en) 2020-01-29 2020-07-14 King Abdulaziz University Mucoadhesive buccal film having a dual release carrier system
CN113908295A (en) * 2021-11-12 2022-01-11 郑州大学第一附属医院 Alprazolam clathrate and preparation method thereof

Also Published As

Publication number Publication date
EP1267941A1 (en) 2003-01-02
CA2401424A1 (en) 2001-10-04
EP1267941B1 (en) 2005-11-23
CA2401424C (en) 2011-02-08
US7202233B2 (en) 2007-04-10
US20050222086A1 (en) 2005-10-06
AU4866001A (en) 2001-10-08
DE60115217D1 (en) 2005-12-29
ES2253364T3 (en) 2006-06-01
DE60115217T2 (en) 2006-07-20
WO2001072338A1 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
CA2401424C (en) Alprazolam inclusion complexes and pharmaceutical compositions thereof
AU712546B2 (en) Inclusion complex containing indole selective serotonin agonist
AU565966B2 (en) Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US6407079B1 (en) Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US7683040B2 (en) Intranasal formulation of rotigotine
US5324718A (en) Cyclodextrin/drug complexation
US10363316B2 (en) Pharmaceutical formulation comprising NSAID and cyclodextrin
US20050090468A1 (en) Novel methylated cyclodextrin complexes
WO2011064474A1 (en) Pharmaceutical composition containing strontium salt, vitamin d, and cyclodextrin
WO1997019703A2 (en) Thyroxine/cyclodextrin complexes and pharmaceutical compositions containing the same
JP2007536228A (en) Taste mask formulation containing sertraline and sulfoalkyl ether cyclodextrin
US20160206641A1 (en) Rapidly-dissolving thin film formulation of water soluble digitalis glycoside for the treatment of congestive heart disease
WO1998018827A1 (en) Inclusion complexes of beta-2-andrenergics for oral mucosal delivery
US6077871A (en) Droloxifene pharmaceutical compositions
JP2000507258A (en) Diclofenac / gamma-cyclodextrin inclusion compound
ZA200207221B (en) Alprazolam inclusion complexes and pharmaceutical compositions thereof.
JPH07165616A (en) Complex composition of cyclodextrin and method for making complex
WO2004082589A2 (en) Nasally administrable, bioavailable pharmaceutical composition of loratadine
Magnúsdóttir et al. The conventional model of drug/cyclodextrin complex formation (salicylic acid/β-cyclodextrin inclusion complex).
HUP0000060A2 (en) Pharmaceutical compositions containing camptothecin
HK1083596B (en) Intranasal formulation of rotigotine
JP2005527615A (en) A novel formulation for parenteral application of sodium channel blockers

Legal Events

Date Code Title Description
AS Assignment

Owner name: FARMARC NEDERLAND BV, NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PENKLER, LAWRENCE JOHN;REEL/FRAME:013817/0793

Effective date: 20020717

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION